Diseases [C] » Respiratory Tract Diseases [C08] » Lung Diseases
Hierarchy View
Subtype Terms (27)
Acute Chest Syndrome
10 drugs (9 approved, 1 experimental)
alpha 1-Antitrypsin Deficiency
24 drugs (13 approved, 11 experimental)
Cystic Adenomatoid Malformation of Lung, Congenital
2 approved drugs
Cystic Fibrosis
283 drugs (134 approved, 149 experimental)
Hemoptysis
7 drugs (6 approved, 1 experimental)
Hepatopulmonary Syndrome
6 approved drugs
Hypertension, Pulmonary
153 drugs (95 approved, 58 experimental)
Lung Abscess
4 approved drugs
Lung Diseases, Fungal
4 drugs (3 approved, 1 experimental)
Lung Diseases, Interstitial
67 drugs (50 approved, 17 experimental)
Lung Diseases, Obstructive
23 drugs (18 approved, 5 experimental)
Lung Injury
11 drugs (9 approved, 2 experimental)
Lung Neoplasms
769 drugs (288 approved, 481 experimental)
Plasma Cell Granuloma, Pulmonary
Pneumonia
230 drugs (143 approved, 87 experimental)
Pulmonary Alveolar Proteinosis
7 drugs (4 approved, 3 experimental)
Pulmonary Atelectasis
10 drugs (9 approved, 1 experimental)
Pulmonary Edema
16 drugs (13 approved, 3 experimental)
Pulmonary Embolism
71 drugs (51 approved, 20 experimental)
Pulmonary Eosinophilia
4 approved drugs
Pulmonary Veno-Occlusive Disease
3 approved drugs
Respiratory Distress Syndrome
191 drugs (101 approved, 90 experimental)
Solitary Pulmonary Nodule
4 drugs (2 approved, 2 experimental)
Tuberculosis, Pulmonary
73 drugs (45 approved, 28 experimental)
Approved Indicated Drugs (5)
Phase 3 Indicated Drugs (87)
human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil)
hydroxychloroquine (plaquenil)
Phase 2 Indicated Drugs (77)
Phase 1 Indicated Drugs (50)
Other Experimental Indicated Drugs (42)
Organization Involved with Phase 4 Indications (167)
All India Institute of Medical Sciences
Baqiyatallah Medical Sciences University
Catalan Society of Family Medicine
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Dutch Health Care Insurance Board
East West Medical Research Institute
Father Sean O'Sullivan Research Centre
Flight Attendant Medical Research Institute
Gottfried Wilhelm Leibniz Universität Hannover
HealthCore-Anthem Research Network
Hospital General Universitario Gregorio Marañon
Hospital of South West Jutland
Huazhong University of Science and Technology
Icahn School of Medicine at Mount Sinai
Isala Clinics, Zwolle, The Netherlands
Katholieke Universiteit Leuven
Los Angeles Biomedical Research Institute
Moorgreen Hospital, Southampton
National Health and Medical Research Council, Australia
National Institute for Health Research, United Kingdom
National Institute for Tuberculosis and Lung Diseases, Poland
People's Liberation Army of China
Rundo International Pharmaceutical Research & Development Co.,Ltd.
Sociedad Española de Neumología y Cirugía Torácica
Spanish Research Center for Respiratory Diseases
Taipei Veteran General hospital
The Korean Academy of Tuberculosis and Respiratory Diseases
The Netherlands Asthma Foundation
Universidad Autonoma de Madrid
Organization Involved with Phase 3 Indications (190)
Ache Laboratorios Farmaceuticos S.A.
Assistance Publique - Hôpitaux de Paris
Biomedical Research and Training Institute Zimbabwe
Blueprint Medicines Corporation
Canadian Institutes of Health Research (CIHR)
Case Western Reserve University
Centers for Medicare and Medicaid Services
Centre Hospitalier Intercommunal Creteil
Clinical Sciences Center University Hospital Aintree
Health Sciences University Sureyyapasa Chest Diseases and Chest Surgery Hospital
Henan University of Traditional Chinese Medicine
Hospital Son Espases, Palma Mallorca
Hospital Universitari Son Dureta
James Cook University Hospital, Middlesbrough, UK
Jiangsu Carefree Pharmaceutical Co., Ltd.
Liaoning Hospital of Traditional Chinese Medicine
Mercy Hospital for Women, Australia
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Child Health and Human Development (NICHD)
National Institutes of Health (NIH)
National Science and Technology Development Agency, Thailand
Nova Scotia Health Research Foundation
Oregon Health and Science University
Patient-Centered Outcomes Research Institute
Postgraduate Institute of Medical Education and Research
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Shanghai University of Traditional Chinese Medicine
South Australian Health and Medical Research Institute
St. Antonius Hospital, Nieuwegein
The University of Texas, Dallas
University of Alabama, Birmingham
University of California, Berkeley
Organization Involved with Phase 2 Indications (125)
Adams Respiratory Therapeutics
Azienda Ospedaliera Antonio Cardarelli
Bangabandhu Sheikh Mujib Medical University
Centre for General Practice for Clinical Trials Unit, Inala
CF Therapeutics Development Network Coordinating Center
Cystic Fibrosis Foundation Therapeutics
Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
Fondazione Don Carlo Gnocchi Onlus
German Center for Lung Research
Innovent Biologics (Suzhou) Co. Ltd.
Institute of Medicinal Molecular Design, Inc.
Institut fuer Atemwegsforschung GmbH, Wiesbaden, Germany
James and Esther King Biomedical Research Program
King Edward VII Hospital, Windsor
National Cancer Institute (NCI)
National Center for Complementary and Integrative Health (NCCIH)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Environmental Health Sciences (NIEHS)
New Horizons Clinical Research
Nordmark Arzneimittel GmbH & Co. KG
Peninsula Chest Clinic, Frankston
Philipps University of Marburg
Pulmonary Associates, Phoenix, AZ
Respiratory Research Foundation, Toorak Gardens
State University of New York, Buffalo
Stichting Astma Bestrijding, The Netherlands
St Joseph's Medical Center, Towson, MD
St. Luke's-Roosevelt Hospital Center
Organization Involved with Phase 1 Indications (29)
Organization Involved with Other Experimental Indications (41)
Centers for Disease Control and Prevention (CDC)
Dalarna County Council, Sweden
Federal University of Health Science of Porto Alegre
Fundación Neumologica Colombiana
Instituto de Molestias Cardiovasculares
Landsforeningen for hjerte og lungesyke (LHL)
Minnesota Veterans Medical Research and Education Foundation
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
